(Bloomberg) -- Life-sciences company Danaher Corp. has stopped pursuing Catalent Inc. after expressing interest in buying the contract manufacturer, according to people familiar with the matter.
According to a report last week, Danaher was no longer considering a takeover of contract manufacturer Catalent Inc (NYSE: CTLT) after expressing interest in buying the company earlier this year.
Despite a multi-billion-dollar takeover bid from Novo Holdings, contract manufacturer Catalent appears to be continuing with the internal restructuring scheme it unveiled last year. For more than ...
(Bloomberg) -- Life sciences company Danaher Corp. has expressed takeover interest in contract manufacturer Catalent Inc., according to people familiar with the matter. Most Read from Bloomberg ...
That means you can get tickets to see the Magic at half price! Act fast, as this offer is available for a limited time only. Wednesday, Mar. 13 7:00 PM Tuesday, Mar. 19 7:00 PM Thursday, Mar. 21 7 ...
Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical ...
Police say they have become aware of a planned youth “takeover” at the Del Amo Fashion Center on Saturday and will beef up security at the mall to thwart any potential problems. Should it ...
Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer ...
Here are some of their reactions. Our View: Biden administration owes the American public and American allies straight talk under oath about the tragic evacuation from the Taliban takeover.
Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments ...
No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...